Page 1 - hypertension_newsletter
P. 1
REFLECTIONS
Hypertension
Hypertension Global Newsletter #10 2026
TABLE OF CONTENTS
KEY ARTICLES
Welcome back to the REFLECTIONS Hypertension
GUIDELINES AND SCIENTIFIC STATEMENTS Global Newsletter series, which draws on the expertise of
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/ international physicians to summarise the latest clinical and
AGS/AMA/ASPC/NMA/PCNA/ SGIM guideline for the real-world evidence in the field of hypertension and reflect
Hypertension
prevention, detection, evaluation and management on the clinical impact of these new data on the management
of high blood pressure in adults: A report of the
American College of Cardiology/American Heart of patients with hypertension. Since our last newsletter,
Association joint committee on clinical practice many new and interesting publications have appeared in the
guidelines. Jones DW, et al. Hypertension. 2025 active field of clinical research in hypertension. Therefore,
Oct;82(10):e212-e316. the Scientific Planning Committee was tasked with choosing
Single-pill combination therapy for the management from an extensive list of articles from high-quality scientific
of hypertension: A scientific statement from
the American Heart Association. King JB, et al. journals. To make this last selection, we privileged novel
Hypertension. 2026 Mar;83(3):e00258. findings rather than confirmation papers, and articles
with a direct application to antihypertensive treatment in
TREATMENT
routine clinical practice. In this newsletter, we will focus
New drug therapies for hypertension. Azizi M, et al.
Lancet. 2026 Mar 7;407(10532):1014-1028. on 1) the latest evolution of clinical practice guidelines,
Quadruple vs triple therapy for resistant 2) advancements in pharmacological management and
hypertension: The QUADRO trial. Taddei S, et al. Eur the strong push for single-pill combinations, and 3) the
Heart J. 2026 Feb 11:ehag022. doi: 10.1093/eurheartj/ integration of machine learning and artificial intelligence into
ehag022. Online ahead of print. clinical care. As with previous newsletters, we invite you to
Blood pressure-lowering efficacy of antihypertensive interact with this newsletter through links to commentary
drugs and their combinations: A systematic review videos from authors of the publications, short video clinical
and meta-analysis of randomised, double-blind,
placebo-controlled trials. Wang N, et al. Lancet. 2025 perspectives from our Scientific Planning Committee, and to
Aug 30;406(10506):915-925. explore the articles in depth through the hyperlinks provided.
MEASUREMENT Prof. Laurent (Chair)
Cuffless devices for the measurement of blood
pressure: A scientific statement from the American
Heart Association. Cohen JB, et al. Hypertension. 2026 SCIENTIFIC PLANNING COMMITTEE
Mar;83(3):e00254.
ARTIFICIAL INTELLIGENCE Prof. Stéphane Laurent Prof. Diego Araiza
(France) (Mexico)
Performance of large language models in analyzing
common hypertension scenarios. Zand J, et al.
Hypertension. 2026 Jan;83(1):225-234.
Artificial intelligence in cardiovascular medicine: Dr. Om Narayan Prof. Zainab Raissuni
Focus on hypertension. Varzideh F, et al. Hypertension. (Australia) (Morocco)
2026 Jun;83(6):e26094.
Artificial intelligence in cardiovascular
pharmacotherapy: Applications and perspectives. Dr. Juan Camilo Dr. Michal Fikrle
Costa F, et al. Eur Heart J. 2025 Oct 1;46(37):3616-3627. Pedreros Guerra (Czech Republic)
(Colombia)
ADDITIONAL ARTICLES OF INTEREST
CONFERENCE CORNER

